Impaired Clearance of Methotrexate in Organic Anion Transporter 3 (Slc22a8) Knockout Mice: A Gender Specific Impact of Reduced Folates
To elucidate the role of the renal basolateral transporter, Oat3, in the disposition of methotrexate.
Materials and Methods
Chinese hamster ovary cells expressing mouse Oat3 were used to determine kinetics and specificity of inhibition of methotrexate transport. Methotrexate clearance was then examined in vivo in wildtype and Oat3 knockout mice.
NSAIDs, ß-lactams, and uremic toxins inhibited mOat3-mediated methotrexate uptake by 70–100%, while folate, leucovorin, and 5-methyltetrahydrofolate inhibited transport by 25–50%. A Km of 60.6 ± 9.3 μM for methotrexate transport was determined. Oat3 knockout mice exhibited reduced methotrexate-to-inulin clearance ratios versus wildtype. Male wildtype mice, but not knockouts or females, demonstrated significantly accelerated methotrexate clearance in response to reduced folates. Reduced folates also markedly inhibited hepatic methotrexate accumulation in males, but not females, and the response was independent of Oat3 function.
Oat3 contributes to methotrexate clearance, but represents only one component responsible for methotrexate’s elimination. Therefore, in patients, dysfunctional hOAT3 polymorphisms or drug competition for hOAT3 transport may severely impact methotrexate elimination only when redundant means of methotrexate removal are also compromised. Furthermore, the present findings suggest that reduced-folate administration only influences methotrexate disposition in males, with the renal reduced-folate response influenced by OAT3 function.
Key wordscancer carrier chemotherapy polymorphisms renal secretion
5-formyltetrahydrofolate (a.k.a. folinic acid or leucovorin)
Chinese hamster ovary cells transfected with empty vector
Chinese hamster ovary cells transfected with murine organic anion transporter 3
the Michaelis–Menten constant
multidrug resistance-associated protein
non-steroidal anti-inflammatory drugs
- OAT or Oat
human or non-human organic anion transporter, respectively
reduced folate carrier 1
- 1.Methotrexate. DRUGDEX® Evaluations. n.d. Thomson Micromedex. 14 Mar. 2007. Available at: http://www.thomsonhc.com.
- 9.M. Kool, M. van der Linden, M. de Haas, G. L. Scheffer, J. M. de Vree, A. J. Smith, G. Jansen, G. J. Peters, N. Ponne, R. J. Scheper, R. P. Elferink, F. Baas, and P. Borst. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U. S. A. 96:6914–6919 (1999).PubMedCrossRefGoogle Scholar
- 13.Y. Nozaki, H. Kusuhara, H. Endou, and Y. Sugiyama. Quantitative evaluation of the drug–drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther. 309:226–234 (2004).PubMedCrossRefGoogle Scholar
- 14.I. Badagnani, R. A. Castro, T. R. Taylor, C. M. Brett, C. C. Huang, D. Stryke, M. Kawamoto, S. J. Johns, T. E. Ferrin, E. J. Carlson, E. G. Burchard, and K. M. Giacomini. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318:521–529 (2006).PubMedCrossRefGoogle Scholar
- 19.T. L. Witt, S. E. Stapels, and L. H. Matherly. Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7–12. J. Biol. Chem. 279:46755–46763 (2004).PubMedCrossRefGoogle Scholar
- 21.A. R. Erdman, L. M. Mangravite, T. J. Urban, L. L. Lagpacan, R. A. Castro, M. de la Cruz, W. Chan, C. C. Huang, S. J. Johns, M. Kawamoto, D. Stryke, T. R. Taylor, E. J. Carlson, T. E. Ferrin, C. M. Brett, E. G. Burchard, and K. M. Giacomini. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am. J. Physiol. Renal. Physiol. 290:F905–912 (2006).PubMedCrossRefGoogle Scholar